Neumora (NMRA) news
Recent news
Perceptive Advisors exits drug, BLTE, EVMN, NMRA in 2Q: 13F
Perceptive Advisors LLC, a biotech-focused investment firm, disclosed its second-quarter 2026 portfolio changes in a recent 13F filing. The firm exited several positions, including drugmaker Belite Bio (BLTE), Evommune (EVMN), and Neumora Therapeutics (NMRA), as part of its strategic rebalancing…
AInvest Wire · Aug 14, 2026Neumora Therapeutics - plans to submit IND application for NMRA-215 in Q4 2026
AInvest Wire · Jul 27, 2026Neuromora Therapeutics Inc: RBC cuts target price to $5 from $7
Neumora Therapeutics, Inc. (NASDAQ: NMRA) recently announced that RBC Capital Markets has adjusted its price target for the company’s stock, reducing it from $7 to $5 while maintaining an Outperform rating. This update follows ongoing developments in Neumora’s clinical pipeline and evolving market…
AInvest Wire · Jul 13, 2026Neumora implemented a reduction in force of about 35%
AInvest Wire · Jun 15, 2026Neumora Therapeutics sees annualized cost savings about $10M
AInvest Wire · Jun 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.